Clinical characteristics of MASLD/MetALD/MAFLD/NAFLD and the relative risk analysis on metabolic disorders

Clinical characteristics of MASLD/MetALD/MAFLD/NAFLD and the relative risk analysis on metabolic disorders

Abstract Objectives Our objective was to compare the clinical features of Metabolic dysfunction-associated steatotic liver disease (MASLD) /metabolic alcohol-related liver disease (MetALD)/metabolic associated fatty liver disease (MAFLD)/nonalcoholic fatty liver disease (NAFLD) and the relative risk...

Full description

Saved in:

Bibliographic Details
Main Authors:	Hong-ye Peng, Chun-li Lu, Mo Zhao, Xiao-qiang Huang, Shu-xia Huang, Zi-wen Zhuo, Jing Liu, Yan-ping Lu, Wen-liang Lv
Format:	Article
Language:	English
Published:	BMC 2025-05-01
Series:	BMC Gastroenterology
Subjects:	MASLD MetALD Metabolic disorders Hypertension T2DM Steatosis severity.
Online Access:	https://doi.org/10.1186/s12876-025-03912-0
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Metabolic dysfunction-associated steatotic liver disease and risk of four intrahepatic and extrahepatic diseases
by: Yiyuan Xiao, et al.
Published: (2025-01-01)

Fucoidan from Fucus vesiculosus alleviates MetALD via promoting HIF-1α ubiquitination to suppress peripheral monocyte infiltration
by: Lei Li, et al.
Published: (2025-08-01)

Comprehensive analysis of peripheral blood free amino acids in MASLD: the impact of glycine-serine-threonine metabolism
by: Masaaki Mino, et al.
Published: (2024-12-01)

Diet quality and physical activity affect metabolic dysfunction-associated steatotic liver disease, metabolic dysfunction and etiology-associated steatohepatitis, and compensated advanced chronic liver disease among United States adults: NHANES 2017–2020
by: Peng Wang, et al.
Published: (2025-01-01)

Body mass index and diabetes predict severity of liver fibrosis across the spectrum of steatotic liver disease
by: Eda Kaya, et al.
Published: (2025-01-01)

MetALD: Clinical aspects, pathophysiology and treatmentKeypoints
by: Jordi Gratacós-Ginès, et al.
Published: (2025-02-01)

Different fungal signatures in ALD and MAFLD
by: Daya Zhang, et al.
Published: (2024-11-01)

DHCR7 inhibition ameliorates MetALD and HCC in mice and human 3D liver spheroids
by: Gen Yamamoto, et al.
Published: (2025-07-01)

Differences in the incidence of cirrhosis-associated complications between MASLD, MetALD and ALD among patients with decompensated liver cirrhosis
by: Laura Buttler, et al.
Published: (2025-01-01)

Differences in the incidence of cirrhosis-associated complications between MASLD, MetALD and ALD among patients with decompensated liver cirrhosis.
by: Laura Buttler, et al.
Published: (2025-01-01)

Current burden of steatotic liver disease and fibrosis among adults in the United States, 2017–2023
by: Donghee Kim, et al.
Published: (2025-04-01)

Glucagon-like Peptide-1 Receptor Agonists (GLP-1 RAs): A Pan-Steatotic Liver Disease Treatment?
by: Lampros Chrysavgis, et al.
Published: (2025-06-01)

Current burden of MASLD, MetALD, and hepatic fibrosis among US adults with prediabetes and diabetes, 2017–2023
by: Donghee Kim, et al.
Published: (2025-07-01)

Gut Microbiota and Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): Emerging Pathogenic Mechanisms and Therapeutic Implications
by: Farah Abdelhameed, et al.
Published: (2025-03-01)

Impact of Gut Microbiome on Gut Permeability in Liver and Gut Diseases
by: Punnag Saha, et al.
Published: (2025-05-01)

MetAP2 as a Therapeutic Target for Obesity and Type 2 Diabetes: Structural Insights, Mechanistic Roles, and Inhibitor Development
by: Dong Oh Moon
Published: (2024-12-01)

Enhanced Visible Light Photocatalytic Activity of Cu-Doped ZnO ALD Films Deposited on Porous Substrates
by: Piltaver Ivna Kavre, et al.
Published: (2024-01-01)

Mitochondrial ROS, a trigger for mitochondrial dysfunction and inflammasome activation and a therapeutic target in liver diseases
by: Hala Saeed Jaara, et al.
Published: (2024-12-01)

Transitioning from NAFLD to MAFLD to MASLD in the Mexican population
by: B.A. Priego-Parra, et al.
Published: (2025-01-01)

Association of metabolic dysfunction-associated steatotic liver disease and steatosis-associated fibrosis estimator with subclinical coronary atherosclerosis: observation cohort study
by: Joonho Jeong, et al.
Published: (2025-07-01)

Deposition of HfO<sub>2</sub> by Remote Plasma ALD for High-Aspect-Ratio Trench Capacitors in DRAM
by: Jiwon Kim, et al.
Published: (2025-05-01)

High-Sensitivity C-Reactive Protein Levels in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD), Metabolic Alcohol-Associated Liver Disease (MetALD), and Alcoholic Liver Disease (ALD) with Metabolic Dysfunction
by: Seong-Uk Baek, et al.
Published: (2024-11-01)

β-Resorcylic acid prevents MASLD in ob/ob mice by modulating lipid metabolism and inflammation in the liver
by: Sergio López-Herrador, et al.
Published: (2025-09-01)

PHARMACOEPIDEMIOLOGICAL EVALUATION OF HEPATOTROPIC THERAPY IN REAL CLINICAL PRACTICE
by: D. V. Blinov, et al.
Published: (2015-06-01)

Consensus Statement on Metabolic Dysfunction‐Associated Steatotic Liver Disease in Children and Adolescents From the Joint TASL‐TSPGHAN Expert Committee
by: Yu‐Cheng Lin, et al.
Published: (2025-06-01)

MASLD vs. MAFLD. A narrative review
by: Amedeo Lonardo, et al.
Published: (2025-08-01)

P-12 METHYL GROUP DONOR SUPPLEMENTATION IN A MetALD MODEL: REGULATION OF GUT MICROBIOTA AND METABOLIC PARAMETERS
by: Carolina Díaz Canul, et al.
Published: (2024-12-01)

Cost-effectiveness of advanced hepatic fibrosis screening in individuals with suspected MASLD identified by serologic noninvasive tests
by: Huiyul Park, et al.
Published: (2025-07-01)

Transitioning from NAFLD to MAFLD and MASLD: the toxic relationship with alcohol consumption
by: Mubin Ozercan, et al.
Published: (2025-01-01)

Düzeltme: Dynamics in between Structural and Electrical Properties of as Grown ZnO Thin Films by Thermal ALD
by: Bilge İmer
Published: (2024-12-01)

The association of the metabolic score for insulin resistance and metabolic dysfunction-related steatosis liver disease: a population-based observational study
by: Haoxuan Zou, et al.
Published: (2025-07-01)

Association between the lymphocyte-to-high-density lipoprotein ratio and metabolic dysfunction-associated steatotic liver disease among US adults: a cross-sectional study from NHANES 2017 to 2020
by: Chuanzhi Tang, et al.
Published: (2024-12-01)

Genetic variants influencing liver fat in normal-weight individuals of European ancestry
by: Ignazio S. Piras, et al.
Published: (2025-08-01)

Glycemic variability in type 2 diabetic patients with metabolic dysfunction-associated steatotic liver disease: a case-control study
by: Yueqiu Wang, et al.
Published: (2025-12-01)

Clopidogrel ameliorates high-fat diet-induced hepatic steatosis in mice through activation of the AMPK signaling pathway and beyond
by: Ting Tai, et al.
Published: (2024-10-01)

MAFLD or MASLD: Which better represents the prognosis of the steatotic liver population: Letter to the editor on “Evolutionary changes in metabolic dysfunction-associated steatotic liver disease and risk of hepatocellular carcinoma: A nationwide cohort study”
by: Ying Wang, et al.
Published: (2025-04-01)

Response to crizotinib in advanced intrahepatic cholangiocarcinoma with ZKSCAN1-MET fusion and MET amplification: case reports and literature review
by: Jian-Hui Wu, et al.
Published: (2025-06-01)

Expert Consensus on Diagnosis and Treatment of NSCLC with MET Abnormalities  (2025 Version)
by: Jun CHEN, et al.
Published: (2025-02-01)

Development of SOCS1 mimetics as novel approach to harmonize inflammation, oxidative stress, and fibrogenesis in metabolic dysfunction-associated steatotic liver disease
by: Susana Bernal, et al.
Published: (2025-07-01)

A prospective study on the role of non-invasive tests in the evaluation of diabetes mellitus associated steatotic liver disease
by: Zülal İstemihan, et al.
Published: (2025-07-01)